DiscGenics is a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine.
Founders
Flagg Flanagan
2007
Company Size
11-50
TechBuzz Articles
DiscGenics Raises $50 Million for Novel Back Pain Treatment, Mark Tullis, October 21st, 2020
Buzzworthy Mentions
DiscGenics Announces Positive Interim Data on Clinical Trial of IDCT Therapy, March 4th, 2022
DiscGenics Completes Enrollment in Japanese Study, April 30th, 2021